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Eosinophilic airway inflammation is a hallmark in the pathophysiologi-
cal and clinical definition of asthma. In the last decades, asthma evolved in 
the recognition of different phenotypes identified by natural history, clinical 
and physiological characteristics, and the underlying immune mechanisms. 
Among these phenotypes, many have been associated with eosinophilic-driven 
inflammation. This is the case of either early-onset allergic Th2 asthma or 
late-onset persistent eosinophilic asthma. Both animal models and analysis 
from human samples have contributed to elucidate the role of eosinophils in 
the asthmatic inflammatory response and the synergic role of Th2 cytokines. In 
severe asthma, high numbers of eosinophils can persist despite treatment with 
inhaled and oral corticosteroids leading to the definition of severe refractory 
eosinophilic asthma. The combined role of IL-4-, IL-13- and IL-5-associated 
pathways has focused the view over the T2-type endotypes, wherein a specific 
biological pathway explains the observable properties of different phenotypes 
and the identifiable biomarkers can predict response to monoclonal antibodies 
directed against a selected immune target. In the era of precision medicine and 
personalized therapy, both the identification of Th2 molecules and eosinophils 
as targets and biomarkers have become the best clue for treating and monitoring 
severe asthma.
Keywords: severe asthma, eosinophilic phenotypes, T2-type inflammation, 
eosinophilic refractory asthma, anti-IL5 treatment
1. Introduction
Asthma and chronic rhinosinusitis (CRS) are chronic inflammatory disorders 
involving the lower and upper airways. According to the definition by Global 
Initiative for Asthma (GINA) documents, asthma is a heterogeneous disease char-
acterized by chronic airway inflammation associated with a history of respiratory 
symptoms such as wheeze, shortness of breath, chest tightness and cough and 
evidence of variable expiratory airflow limitation [1]. Airway inflammation is 
usually present and persists even when symptoms are absent or lung function is 
normal.
In the last decades, the role of chronic airway inflammation has been cen-
tral in the definition of asthma that was recognized as a chronic inflammatory 
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disorder in which many cells and cellular mediators play a role and result in the 
characteristic pathophysiological changes [2]. The inflammation involves all the 
airways from the main bronchi to the peripheral small airways. A characteristic 
pattern of inflammation has been described in asthma involving inflammatory 
cells mainly mast cells, eosinophils, T lymphocytes, dendritic cells, macrophages 
and neutrophils, which release mediators that induce symptoms. Both animal 
models and analysis from human samples have contributed to elucidate the type 
of inflammation involved in asthma [3]. The most common phenotype of asthma 
is characterized by eosinophilic airway inflammation and the role of eosinophils 
as a key player in the pathophysiology of asthma is well documented. Eosinophils 
emerged as leading cells from the first post-mortem studies of asthmatic lungs, 
passing through the finding of increased in number and activation status of 
eosinophils in asthmatic airways [4] and of increased eosinophil surrogates as 
fractional exhaled nitric oxide (FENO) [5]. Nowadays, the focus is on the defini-
tion of the forms of uncontrolled or severe eosinophilic asthma in which airways, 
sputum and blood eosinophils are consistently increased and represent a bio-
marker of the eosinophilic endotype of asthma and a guide for biologic target 
therapies [6, 7].
2. Eosinophils and allergic asthma
Allergen challenge models have been conceived to reproduce many features of 
clinical asthma [8]. Actually, atopy, which is the production of allergen-specific 
IgE antibodies, is a predisposing factor for asthma development, and birth cohort 
studies have shown that sensitization to allergens such as house dust mite, cat and 
dog dander and Aspergillus is independent risk factors for wheezing in children [9]. 
Moreover, exposure to allergens is one of the most recognized environmental fac-
tors that trigger asthma symptoms. The term allergic asthma has been used to define 
the presence of sensitization to environmental allergens and the clinical correlation 
between exposure and symptoms, both indoor and outdoor allergens being well-
known triggers of asthma exacerbations [10].
Both allergen challenged animal models of asthma and allergic asthma in 
humans are associated with a T-lymphocyte CD4+ Th2-polarized response as the 
main feature of airway inflammation. The allergic response is characterized by 
immediate and late inflammatory responses in which Th2 cells govern the inflam-
matory cell recruitment and activation by the release of the signature cytokines 
IL-4, IL-5 and IL-13 as well as IgE antibody synthesis.
2.1 Mouse models of allergic asthma
In acute allergen challenged mouse models of asthma, after the sensitiza-
tion period (usually 14–21 days), the animal is challenged with the allergen via 
the airway and this causes many key features of clinical asthma. The analysis of 
bronchoalveolar lavage (BAL) and bioptic samples of airway walls has supported 
the hypothesis that asthma is a Th2-mediated disease. A dominating influx of 
eosinophils has been demonstrated and related to the development of AHR 
[11]. Moreover, the adoptive transfer of Th2 cells into recipient mice was able to 
 reproduce airway eosinophilia, mucus hypersecretion and AHR after allergen 
inhalation [12].
However, some of these effects resulted in transient changes and do not involve 
structural changes. Through chronic allergen exposure in mice, allergen-dependent 
sensitization, Th2-dependent allergic inflammation, eosinophilic influx into the 
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airway mucosa, mucus overproduction and AHR have been reproduced [11, 13]. 
Generally, acute and chronically treated mice had similar early and late asthmatic 
responses; however, the acute model had higher levels of eosinophilia, whereas the 
chronic model showed hyperresponsiveness to lower doses of methacholine and had 
higher total IgE. On the other hand, many of the lesions observed in chronic human 
asthma, such as chronic inflammation of the airway wall and airway remodeling 
changes, are absent.
Moreover, transgenic mice that overexpress the Th2 cytokines—IL-4, IL-5, IL-13 
and IL-9—in the airway epithelium exhibit the same inflammatory features. IL5 is a 
Th2 cytokine essential for differentiation, maturation and survival of eosinophils. 
A key role in allergen-induced inflammatory responses has been shown in murine 
IL-5-deficient model chronically challenged with an allergen in which the eosino-
philia, lung damage and airway hyperreactivity were abolished. The reconstitution 
of IL-5 production using recombinant vaccinia virus that expressed IL-5 restored 
eosinophilia and airway dysfunction [14]. Using a clinically relevant model of 
chronic allergic asthma in mice, Kumar RK et al. showed that anti–IL-5 inhibited 
inflammation in terms of accumulation of eosinophils in the tracheal epithelium 
and inflammatory cells in the lamina propria, but had no effect on airway respon-
siveness to methacholine [15].
Many studies have demonstrated the significant role of IL/4IL-13 pathway in 
asthma. Through the agonization of IL-4R, both IL4 and IL13 activate a tyrosine 
kinase-dependent signal that after phosphorylation of STAT6 regulates the tran-
scription of Th2-involved genes. Models of IL-4−/− mice were protected from 
the development of AHR and aspects of remodeling, while the administration of 
soluble IL-4 receptor reduced inflammation and mucus hypersecretion, but had no 
effect on AHR [8] Similarly, soluble IL-13 suppressed pulmonary inflammation but 
had a limited effect on AHR [15].
Limitations evidenced in mouse models are that inflammation is not restricted 
to the conducting airways, but extended to vascular and parenchymal parts of 
the lung; moreover, some of the clues of asthma inflammation such as the large 
increases in airway smooth muscle and MC infiltration are not generally observed.
2.2 Human models of allergic asthma
In humans, the role of Th2 cytokines and eosinophils in allergic asthma comes 
from many experimental data that in part differ from the mice models.
Sensitizations to environmental allergens in allergic subjects are documented 
by positive skin prick test reactions and elevated allergen-specific IgE serum levels. 
Activation of FcεRI on mast cells and basophils by allergen-bound IgE induces the 
release of preformed vasoactive mediators, which rapidly elicit edema of the bron-
chial mucosa, mucus production and smooth muscle constriction. This mechanism 
is confirmed by the increased numbers of cells expressing the high-affinity receptor 
for IgE (FcεRI) in allergic asthmatic tissues [16].
Biopsies from bronchial mucosa show CD4+ cell infiltrates and enhanced 
expression of Th2-type cytokines and chemokines. IL-4 and IL-5 mRNA were 
localized in activated T cells (CD3+), mast cells (tryptase +) and activated 
eosinophils (EG2+) both in BAL and bronchial biopsies from mild atopic 
asthmatic patients [17], and the number of activated CD4+ T cells and IL-5 
mRNA positive cells is increased in asthmatic airways following antigen chal-
lenge. This skewed cytokine involvement is reflected by the expression of the 
transcriptional regulators GATA-3 (GATA binding protein 3) after segmental 
allergen challenge in asthmatics [18]. GATA-3 is a transcriptor factor that finds 
its binding site in the IL-5 promoter and induces Th2 cytokine gene expression 
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by biasing Th1/Th2 balance. The increase in GATA-3 expression in the asthmatic 
subjects correlated significantly with IL-5 expression and AHR [19]. In sum-
mary, CD4+ Th2 cells are believed to initiate and perpetuate the inflammatory 
response in allergic asthma.
IL-5 expression is increased 18–48 h after allergen challenge in BAL 
samples in mite-associated bronchial asthma when they were stimulated with 
Dermatophagoides farinae [20]. The levels of IL-5 mRNA-positive cells and IL-5 
correlate with the number of eosinophils infiltrating the bronchial mucosa and 
BAL of asthmatic subjects, with pulmonary function and symptom severity [21]. 
Biopsies from the respiratory mucosa of allergic asthmatics show the enhanced 
expression of other Th2-type cytokines and chemokines such as IL-4, IL-6, IL-9, 
IL-10 and IL-13. Allergen challenge induces in patients with asthma IL13 and IL4 
release in BAL and sputum eosinophils that positively correlate with IL-13 expres-
sion in asthmatic bronchial submucosa [22]. IL13 is thus involved in the regulation 
of allergen-induced late-phase inflammatory responses. IL-13, indeed, can modu-
late the production of IgE through the isotype class switching of B cells; therefore, it 
is involved in the early phase of allergic reactions.
2.3 Recruitment of eosinophils in allergic asthma
Eosinophils are recruited from progenitors after allergen exposure. Levels of Eo 
progenitors arise in the peripheral blood after seasonal allergen exposure, during 
controlled exacerbations of atopic asthma and after single allergen challenge to the 
airways in atopic asthmatics and animal models. Trafficking of these cells from 
the bone marrow, where they are produced, to the airways was also demonstrated. 
In fact, these CD34+ CD45+ progenitors express the IL-5 receptor alpha and are 
recruited by IL5 and GM-CSF produced in asthmatic airways, subsequently acquir-
ing an activating form that reaches the inflamed airways [23]. Eosinophilopoiesis 
develops after 24 h from allergen challenges and is followed by the accumulation of 
eosinophils in the airways.
2.4 Eosinophils in different phases of allergic asthma
The sensitization phase is supposed to be determined by the differentiation of 
Th naive cells into Th2 lymphocytes. Dendritic cells (DCs) in response to allergen 
stimulation drive a Th2-oriented response. DC subsets have been described to 
respond to various stimuli coming from the inflammatory milieu generated after 
the allergenic encounter. Myeloid CD1c + DCs respond to thymic stromal lympho-
poietin (TSLP) produced by the epithelium after allergen encounter by activating 
allergen-specific memory CD4+ cells [24]. Eosinophils also contribute to the initia-
tion phase of Th2 response by suppressing the Th1/Th17 pathway.
The main role of eosinophils in asthmatic response is yet related to the effector 
phase of the inflammatory response. After allergen challenge, asthmatics generally 
develop immediate bronchoconstriction, the so-called early asthmatic response, 
which is maximized within 30 min and resolves between 1 and 3 h. A proportion 
of subjects develop a second, delayed bronchoconstrictor response, named the late 
asthmatic response, which is characterized by prolonged AHR and pronounced 
airway eosinophilia [25]. So it can be assumed that in isolated early responders a 
significant or sustained eosinophilic response does not develop. On the other hand, 
the so-called dual responders develop a sustained IL-5-dependent eosinophilic 
response in terms of both bone marrow recruitment and sputum accumulation. 
This response is accompanied by increases in circulating eosinophils, greater 
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increases of activated eosinophils in the airways, and the development of airway 
hyperresponsiveness [26].
Recruited eosinophils in the airways release a variety of toxic products, oxygen 
radicals, granule-associated cytotoxic proteins and membrane-derived proinflam-
matory mediators that damage the bronchial epithelium and increase AHR.
IL-5 is the most important constituent increasing eosinophil survival, 
recruitment, degranulation and lung injury following inhalation of antigen, as 
demonstrated in a segmental antigen lung challenge model [20], and the levels of 
eosinophils and their cationic proteins in the BAL fluid following allergen challenge 
correlate with the magnitude of the late phase response. Moreover, a positive corre-
lation between the percentage of BAL eosinophils and the ECP was demonstrated at 
baseline but not after 4–6 h after allergen inhalation, thus suggesting that eosino-
phil recruitment and activation seem to follow different temporal kinetics [27].
The effect of IL-5 on eosinophils is demonstrated by the finding of increased 
expression of the alpha chain of IL-5R mRNA in the bronchial biopsies of atopic 
and nonatopic asthmatic subjects; the membrane-bound aIL-5R is coexpressed with 
EG2 in the eosinophils within the bronchial mucosa of asthmatics and inversely 
correlated with FEV1 [28].
2.5 Eosinophilic chemokines in allergic asthma
IL-5 acts as chemotactic factors for eosinophils, promoting eosinophil-endo-
thelial adhesion by inducing the expression of VCAM-1 on endothelial cells. In 
turn, VCAM-1 may bind to integrins on the eosinophils leading to the migration of 
eosinophils to sites of airway inflammation. Blood eosinophils stimulated with IL-5 
adhere to VCAM-1 via the integrins α4β1 and αMβ2 that are the major eosinophil 
integrin-mediating cell adhesion [29]. Eosinophils obtained from BAL after seg-
mental antigen challenge have both β1 and β2 integrins in a high-activity conforma-
tion and adhere to VCAM-1 to a higher degree than blood eosinophils [30]. It seems, 
therefore, that blood eosinophils are primed by IL-5 or P-selectin (expressed by 
platelets) to an integrin activation status and are consequently arrested in vessels of 
inflamed bronchi and move into lung tissue. It is remarkable that the administration 
of anti–IL-5 can lower β2 integrin activation [31]. IL-5 not only has got the ability to 
prime eosinophils for subsequent activation but also enhances their survival at sites 
of allergic inflammation.
The role of other chemokines in allergic asthma is sustained by different pieces 
of evidence. Eotaxin and regulated on activation, normal T-cell expressed and 
secreted (RANTES) act on eosinophils inducing chemotaxis as well as specifically 
activation. In human challenges with the HDM allergen, the peak of eosinophils 
immunopositive for eotaxin, RANTES and IL-5 occurs at 7 h after allergen inhala-
tion, but persisting eosinophilic airway inflammation and AHR remained for 7 days 
after allergen inhalation [32].
These chemokines are released by several cell types in the lung: endothelial cells, 
epithelial cells, fibroblasts, DCs and smooth muscle cells. Eotaxin creates a chemo-
tactic gradient so that eosinophils pass the endothelium of the blood vessels and 
migrate to the site of inflammation [33]. Eotaxin has the potential to mobilize eosin-
ophils and their progenitors from bone marrow and this effect is potentiating with 
that of IL5. Second, in atopic asthmatic patients, high concentrations of eotaxin 
in BAL fluid are detected as well as an increased expression of eotaxin mRNA and 
protein in the epithelium and submucosa of their airways. In the airways of allergic 
asthmatics, eotaxin is in sufficient concentrations to exert chemotactic activity on 
eosinophils in vitro and this effect is enhanced by IL-5 [34].
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RANTES is also found in high concentrations in the sera in allergic asthma, as 
well as monocyte chemoattractant protein-1 and -3 (MCP). These chemokines play 
a role in ongoing lung inflammation, lung leukocyte infiltration, bronchial hyper-
responsiveness and the recruitment of eosinophils.
Eotaxins and RANTES bind to the CCR3 receptor expressed on Th2 cells, 
eosinophils and basophils. Eosinophils in CCR3R knockout mice reach the blood 
vessels and the endothelium but fail to migrate into lung tissue. Indeed, these mice 
are protected from AHR after allergen challenges [35]. After antigen challenge, the 
percentage of CCR3+ eosinophils is downregulated on BAL eosinophils compared 
with peripheral blood eosinophils, while other chemokine receptors like CCR4, 
CCR9 and CXCR3 do not, being predominantly involved in activation of eosinophil 
effector responses [36].
The relationships between the levels of eosinophilic chemokines and AHR or 
bronchoconstriction are not documented in the same way. Some data suggest that 
mediators released by cells other than eosinophils, similar to MCs or basophils, can 
contribute to AHR. In addition, chemokine receptors might be involved in the activa-
tion of airway eosinophils for degranulation or prolonged survival. Even if antagonists 
derived from peptides and small molecules exist to block the chemokine receptor 
CCR3, the in vivo effect on airway inflammation is not sufficiently proved [33].
Once activated, eosinophils may produce effector molecules like eosinophil 
major basic protein and eosinophil-derived neurotoxin and degranulate at the site 
of injury contributing to tissue damage in the asthmatic lung. These molecules 
have cytotoxic effects on respiratory epithelium, facilitate the entry of other toxic 
molecules and trigger the degranulation of mast cells and basophils. In asthmatic 
airways, eosinophils also take part in respiratory-burst–oxidase reactions and 
generate large amounts of cysteinyl leukotrienes that contribute to increase vascular 
permeability, mucus secretion and smooth muscle contraction [37].
2.6 Local eosinophilopoiesis
It has been proposed that CD34+ IL-5Ra+ progenitors after mobilization from 
the BM during allergen challenge are able to undergo in situ differentiation at the 
site of allergic inflammation. Actually, CD34+45+IL-5Rα+ progenitors are increased 
in BAL in mouse models after allergen challenge and precede an increase in BAL 
eosinophils through a local differentiation via an IL-5-dependent mechanism [38]. 
Moreover, the CD34+ eosinophil committed pool is maintained within the airways 
via autocrine IL-5 release and IL-5-induced upregulation of IL-5R. CD34+/IL-5Rα 
mRNA+ cell number is increased in the airways of asthmatic subjects and related 
to asthma severity [39]. Surprisingly, eosinophilic precursors persist in the sputum 
of severe asthmatics that are prednisone resistant after anti-IL-5 treatment [40] 
and it has been documented that anti-CCR3 strategies do not suppress circulating 
and airway eosinophils in moderate-to-severe asthmatics. Consequently, it can be 
hypothesized that blocking local differentiation and expansion of CD34+/IL-5Rα+ 
cells may reduce eosinophilic inflammation in the airway in asthma.
2.7 Other mechanisms of eosinophil activity into allergic asthmatic airways
Allergic inflammation is locally perpetuated in the airway by the cross-talk 
between eosinophils and other resident cells. MCs are activated by MPB and stem 
cell factor (SCF), both released by eosinophils, contributing, by their direct effects 
on mast cells, to the perpetuation of allergic inflammation [41].
Eosinophils can also affect fibroblast properties, modulating the process of 
tissue remodeling. First, eosinophils are the main source in asthma of transforming 
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growth factor-beta (TGF-β) that induces proliferation and regulates fibroblast 
function as well as controls the production of proteins of the extracellular matrix 
(ECM). In turn, tumor necrosis factor-α (TNF-α) derived from mast cells enhances 
TGF-β synthesis from eosinophils as well as fibroblasts promote survival of MCs 
and eosinophils by releasing SCF and granulocyte–macrophage-colony stimulating 
factor (GM-CSF) [42]. Anti-IL-5 humanized monoclonal antibody has been shown 
to decrease the deposition of many ECM proteins such as collagen III in the RBM 
of mild atopic asthmatics as well as the number of eosinophils and the degree of 
TGF-α in the BAL fluid [43].
In addition, eosinophils express basic fibroblast growth factor (β-FGF) and 
VEGF in the submucosa of asthmatic subjects and release many pro-angiogenic 
cytokines such as IL-8, IL-6, TGF-β and GM-CSF.
The effect on T-cell immune modulation of eosinophils is more controversial. 
Cytokine produced by eosinophils may directly influence T-cell selection by DCs 
determining T-cell tolerance or activation. One example is the induction by IFN-γ of 
indoleamine 2,3-dioxygenase (IDO) in eosinophils that in turn converts tryptophan 
(TRYP) to kynurenine (KYN) inducing apoptosis in Th1 cells, while Th2 cells are 
spared from KYN-induced apoptosis by IL-4 [44].
3. Eosinophils in nonallergic asthma
The increase of the number of activated Th2 lymphocytes and eosinophils, as 
well as IL-5 levels, in both BAL fluid and bronchial biopsies from intrinsic asthmat-
ics, has been extensively reported [45]. No difference between atopic and intrinsic 
asthmatics have been observed in studies examining the expression of high-affinity 
IgE receptor, IL-5 and IL-4 mRNA and protein expression in bronchial biopsies 
[16]. Actually, total serum IgE levels have been noted to be increased in the serum 
of patients with intrinsic asthma. This reflects the increases in Iå and Cå RNA+ cells 
in the bronchial mucosa and provides evidence for a local IgE synthesis even in the 
absence of a known antigen or allergen trigger.
Eosinophilic infiltration in nonallergic asthma can be even much more than 
in allergic asthma and this fact is reflected by the finding of a larger amount of 
RANTES in the bronchoalveolar lavage fluid of patients with nonallergic asthma 
compared with patients with allergic asthma [46].
Attempts to differentiate the inflammatory cascade between allergic and 
nonallergic asthma have proposed a different signal in the Th2 pathway of 
nonallergic asthma attributed to reduced signal transducer and activator of 
transcription 6 (STAT6) expression and consequently reduced IL-4R signaling in 
nonallergic asthma [47]. Another peculiar finding was the increased expression 
of GM-CSF receptor alpha expression in the macrophages detected in mucosa 
and BAL. Peripheral blood eosinophilia is present both in allergic and nonal-
lergic asthma, in some studies being higher in the former compared to the latter 
group [48].
4. The eosinophilic phenotype of asthma
Different attempts have been found in order to identify an eosinophilic phe-
notype of asthma. Eosinophilic asthma is reported to account for approximately 
50–60% of the total asthma population. The definition of eosinophilic asthma 
implies that eosinophils are the dominant cells responsible for the pathophysiologi-
cal changes of the disease. The pathogenic role of eosinophils in these patients is 
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demonstrated by their increased number and status of activation in the airways, 
and consequently, they are detected in sputum, bronchoalveolar lavage, or bron-
chial mucosa or submucosa. These findings may be persistent and associated with 
severe or uncontrolled asthma [7].
Eosinophils may be demonstrated in the airways in the bronchial mucosa or 
submucosa or in the lumen (in the bronchial wash, BAL, or sputum). Bronchial 
biopsy is not routinely used as it is an invasive procedure and practicable only far 
from exacerbations to avoid dangerous complications and the quantification of 
eosinophils in BAL is not standardized and generally reflects samples of the periph-
eral airways.
Sputum examination is currently the most comprehensive and noninvasive 
method for measuring airway inflammation, processing and analysis being stan-
dardized and reliability, validity, and responsiveness proven [49].
The definition of “eosinophilic asthma” implies the existence of noneosinophilic 
asthma. A large cohort of patients with mild-to-moderate asthma in longitudinal 
studies resulted in approximately 50% of them with the absence of eosinophilic 
airway inflammation. The cellular pattern in noneosinophilic asthma may result in 
either predominant neutrophilic inflammation or normal sputum cell count. Within 
eosinophilic asthma, eosinophilia may result in persistent (22%) or on at least 1 
occasion (intermittent eosinophilia, 31%) under multiple sputum examinations [50]. 
Sputum inflammatory granulocytes may identify phenotypic subgroups of differing 
pathology and clinical characteristics within asthmatics. Within the Severe Asthma 
Research Program (SARP), which included a population of severe and nonsevere 
patients with and without corticosteroid treatment, the stratification in four groups 
by granulocyte % in sputum showed significant clinical differences. Patients 
were divided combined for stratification by granulocytes in <2%Eos + <40%Neu, 
<2%Eos + ≥ 40%Neu, ≥2%Eos + <40% Neu, and ≥ 2%Eos + ≥40%Neu. In this study, 
eosinophilic asthma, indicated by ≥2%Eos, accounted for 31% of patients, those 
being with combined increased sputum eosinophils and neutrophils the most severe 
patients in terms of lowest lung function measures, worse asthma control, greatest 
symptoms and use of healthcare resources [51]. In another retrospective series of 508 
asthmatics, the proportion of patients with raised sputum eosinophil counts ≥3% was 
42% independent of the exclusion of steroid-treated patients. Eosinophilic phenotype 
exhibited higher atopy, levels of IgE, bronchial hyperresponsiveness to methacholine, 
FENO levels and lower asthma control, while the mixed granulocytic phenotype, 
with both eosinophilic and neutrophilic inflammation, had the lowest lung function 
and the highest degree of bronchial hyperresponsiveness to methacholine [52].
In most mild-to-moderate asthma patients untreated with steroids, sputum 
eosinophilia >2% was significantly and inversely associated with PC20 methacho-
line identifying 69% of the asthma group [53]. Sputum eosinophils correlate, in 
addition, with symptom score and FEV% and, as previously reported, are increased 
by exposure to common allergens. The association between asthma exacerbations 
and sputum eosinophilia is suggested by different pieces of evidence. First, sputum 
eosinophil count is able to predict asthma deterioration after cessation of ICSs 
treatment in mild-to-moderate asthma, while it is decreased by treatment with 
corticosteroids [54]. Sputum eosinophilia may be a good additional predictor of 
FEV1, PC20 methacholine or quality of life of response to inhaled steroids [55].
Consequently, a clinical strategy, based on re-administration of ICSs when a 
change in sputum eosinophil percentage by using the 0.8% threshold was reached, 
could lower the rates of asthma deteriorations and the number of individuals 
treated with ICSs by 48%. In addition, an increase in sputum eosinophils is detected 
up to 3 months before the development of a clinical exacerbation [56]. The useful-
ness of sputum cell count to improve treatment has been shown by Green et al. that 
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showed the efficacy of reducing exacerbations when treatment was guided accord-
ing to the sputum eosinophils (to achieve a sputum eosinophil count of less than 
3%) [54]. A different study used sputum cell counts to guide corticosteroid therapy 
to keep eosinophils <2% in moderate-to-severe asthma resulting in the sputum 
strategy group lower number and milder exacerbations (overall risk of exacerba-
tions by 49%, it reduced the number of severe exacerbations) that were prevalently 
noneosinophilic [57].
Management of asthma-inhaled corticosteroid treatment based on sputum 
eosinophil levels has been the object of a Cochrane review that concluded that 
actually the risk of exacerbations is significantly reduced compared to that based on 
clinical symptoms with or without lung function, as well as the rate and severity of 
exacerbations defined by requirement for use of oral corticosteroids and hospital-
izations [58]. Sputum eosinophilia may, therefore, be considered a modifiable risk 
factor to reduce exacerbations. Small studies in selected populations have suggested 
increasing ICS dose independent of the level of symptom control.
In this contest, the eosinophilic subtype of asthma may be defined as symptom-
atic asthma in the presence of airway eosinophilia and that is characterized gener-
ally by a good response to glucocorticosteroids.
5. Eosinophilic refractory severe asthma
When eosinophilic inflammation in asthma leads to uncontrolled disease, the 
patient is at risk of exacerbations. In a proportion of patients, asthma becomes dif-
ficult to be treated despite the adequate use of high-dose corticosteroid treatment. 
Once the management of modifiable factors such as incorrect inhaler technique, 
poor adherence, smoking or comorbidities is optimized but asthma remains still 
uncontrolled, the diagnosis of severe asthma can be formulated [59].
In a subgroup of patients with severe asthma, eosinophilic inflammation is still 
active despite the high-dose ICS treatment or oral corticosteroid intake. The use 
of sputum cell counts was thus defined as a marker allowing the identification of 
a subgroup of subjects with severe eosinophilic asthma who were at risk of more 
frequent asthma exacerbations [60].
In patients with severe eosinophilic asthma, sputum eosinophils may be sup-
pressed by using increasing doses of inhaled steroids reducing the number of sub-
sequent exacerbations [54, 57]. Yet, the persistence of airway eosinophilia in these 
subjects reflects a failure of usually adequate doses of corticosteroid to suppress 
inflammation [61]. Corticosteroid insensitivity is therefore intrinsic in the defini-
tion of severe asthma resulting in persistent lack of control despite corticosteroid 
therapy or worsening of asthma control on reduction or discontinuation of cortico-
steroid therapy [62]. A majority of severe asthmatics are corticosteroid dependent, 
refractory or insensitive and require oral corticosteroids (OCS) in addition to ICS to 
maintain some degree of asthma control. Only a small portion of severe asthmatics 
can be considered completely “corticosteroid unresponsive” or resistant [63]. The 
proportion of asthmatics with corticosteroid insensitivity is confirmed from the 
fact that one-third of the current SARP cohort were on regular OCS, with over half 
needing more than three bursts of OCS in the previous year [64].
A dose-response relationship between the use of OCS in asthmatic patients and 
the risk of many adverse events has been documented. Long-term exposure to OCS 
leads to increased risk of osteoporosis, arterial hypertension, diabetes, metabolic 
syndrome, cataracts, gastrointestinal bleeding and neuropsychiatric diseases such as 
depression [65]. The negative effect of systemic corticosteroid is associated not only 
to its maintenance or use but also to cumulative prescriptions of OCS burst [66].
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In the global strategy for asthma management and prevention (GINA) 2019 
update, sputum eosinophilia ≥2% is presented as a criteria to identify patients with 
severe asthma with refractory type 2 inflammation despite high-dose ICS or daily 
OCS treatment [1, 59].
Type 2 high asthma was initially used to identify the eosinophilic phenotype of 
asthma. The current concept of type 2 asthma includes a phenotype, characterized 
by the release of signature cytokines like interleukin IL-4, IL-5 and IL-13 from cells 
of both the innate and the adaptive immune systems. Th2 cells and type 2 innate 
lymphoid cells (ILC2s) are primarily responsible for the production of high levels 
of T2 cytokines in the airways. The demonstration of this cytokine pathway from 
cellular to molecular and transcriptomic levels represents the signature for type 2 
(T2) asthma [67]. The importance of identifying different phenotypes of asthma 
has been addressed by hypothesis-based and unbiased analyses that showed differ-
ent characteristics of asthma phenotype in terms of severity, functional and clinical 
features, comorbidities, prognosis and response to treatment [68].
5.1 Severe eosinophilic asthma in cluster analysis
Asthma phenotyping has involved biased and unbiased approaches with the aim 
of grouping clinical, physiological and genetic characteristics.
In the TENOR study (the epidemiological and natural history of asthma: 
outcome and treatment regiments), a severe allergic asthma phenotype emerged 
as a high-risk group of patients for severe exacerbations with early-onset, IgE and 
allergen sensitization [69]. The existence of this population was confirmed in the 
cluster analysis by Haldar P and coworkers who found an early-onset atopic asthma 
cluster in which a concordance between symptom expression and eosinophilic 
airway inflammation is present and a symptom-based approach to therapy titration 
may be sufficient. On the other side, a marked discordant cluster with late-onset 
active predominant eosinophilic inflammation emerged as a refractory phenotype 
of severe asthma [70].
The predominance of sputum eosinophilia in the inflammatory patterns of 
severe asthmatic subphenotypes is confirmed in the unsupervised hierarchical 
cluster analysis of the Severe Asthma Research Program cohort where cluster 4 of 
severe asthmatics was associated to atopic disease and reversible severe reductions 
in pulmonary function, while cluster 5 was characterized mainly by later-onset 
disease and airflow limitations that remain with a FEV1 < 80% predicted [71].
The expansion of this analysis using a supervised learning approach that 
included blood, bronchoscopic, exhaled nitric oxide and clinical data gave a further 
focus on severe asthma phenotypes. Therefore, while cluster 4 resembled that 
previously described with early-onset allergic asthma with low lung function and 
eosinophilic inflammation, the eosinophilic refractory asthma could be further 
split into cluster 5, characterized by late-onset severe asthma with nasal polyps and 
eosinophilia and cluster 6 with persistent inflammation in blood and bronchoal-
veolar lavage fluid, increased FENO levels and exacerbations despite high systemic 
corticosteroid use and side effects. Consequently, cluster 5 was characterized as 
more prone to respond to corticosteroid treatment, even if rapidly deteriorated 
after discontinuation (corticosteroid dependent), while cluster 6 was characterized 
to be corticosteroid complete insensitivity [72].
5.2 Blood eosinophilia as a biomarker of severe eosinophilic asthma
The question of whether blood eosinophilia may be considered, in this con-
test, a surrogate marker of airway eosinophilia, is debated. The measurement of 
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eosinophil counts in blood is inexpensive and widely available. However, blood 
eosinophilia is nonspecific for asthma and often asthmatic patients have normal 
levels of eosinophils. In asthmatics with increased blood eosinophilia, there exists 
a direct correlation with symptom scores and an inverse correlation with FEV1 in 
both children and adults, independently of atopy [73].
Blood eosinophilic counts have been reported to exhibit a moderate-to-good 
correlation with sputum eosinophils in asthma in large cohorts of asthmatics. A 
high blood eosinophil count >220/mm3 resulted in good predictors of sputum 
eosinophilia ≥3% as revealed by an AUC of ROC curves of 79% that yielded 77% 
sensitivity and 70% specificity and an independent factors associated with the pres-
ence of sputum eosinophilic inflammation in multiple logistic regression models 
[52]. Other studies confirmed that blood eosinophils are an accurate biomarker of 
eosinophilic airway inflammation comparing two independent cohorts, mild-to-
moderate asthma versus moderate-to-severe asthma. The authors used a cut-off 
point of ≥0.27 × 109/L blood eosinophils that were able to differentiate eosinophilic 
inflammation of ≥3% with a sensitivity of 78% and specificity of 91% [74].
In a multiple clinical variable analysis within the SARP cohort, the sensitivity 
and specificity of blood eosinophil counts of greater than 300/mL to detect an 
“eosinophil phenotype” based on sputum eosinophil counts of greater than 2% were 
59% and 65%, respectively. This means that a blood eosinophil count of less than 
300/L yields a 41% false-negative that has yet a sputum eosinophil percentage of 
greater than 2%, and likewise, many subjects with sputum eosinophil count of less 
than 2% would also be misclassified with a false-positive rate of 35%. Therefore, 
although statistically significant, the AUC of the ROC curve for predicting sputum 
eosinophil percentages of less than 2% or 2% and greater shows fair-to-poor accu-
racy and positive predictive values. These results are not improved when the cut-off 
of sputum eosinophil counts is more than 3% or whether the analysis is restricted to 
subjects with severe asthma only [51]. The stratification of SARP subjects based on 
blood eosinophil counts of less than 300 or 300/mL and greater showed significant 
differences only in methacholine bronchial hyperresponsiveness (log PC20), FEV1 
percent predicted and FEV1/FVC ratio, neither in any variable related to overall 
asthma health care use or frequency and severity of exacerbations. This not-
enthusiastic result has been confirmed both in patients with mild-to-moderate or 
in those with severe asthma who entered a clinical trial for mepolizumab for severe 
eosinophilic asthma [6].
In a study that evaluated 75 uncontrolled asthmatic patients, a significant posi-
tive relationship between the percentage of sputum eosinophils and the percentage 
of blood eosinophils (r = 0.3647; p = 0.0013) was demonstrated. An important 
limits of this study were the cut-off point of blood eosinophils of 2% of WBC and 
again the low accuracy of ROC curves [75].
Increasing the peripheral blood eosinophil cut-off percentage (2.7% or 
0.26 × 109/L) yielded a significant higher sensitivity and specificity and AUC 
as a diagnostic biomarker of sputum eosinophilia (≥3%) in a population of 
uncontrolled asthmatics [76] suggesting that blood eosinophils can be used in the 
clinic for detecting airway eosinophilia in uncontrolled asthma. These data are 
confirmed when looking at the population selected for treatment with reslizumab, 
another anti-IL-5 mAb, in which blood eosinophil counts of greater than 400/mL 
might be able to improve the prediction of sputum eosinophil counts of greater 
than 3% [77].
A systematic review and meta-analysis estimated the diagnostic accuracy of 
markers for airway eosinophilia in patients with asthma. Looking at the 14 studies 
that investigated blood eosinophils as a predictor marker, an overall modest ability 
to distinguish between patients with or without airway eosinophilia was reported 
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with a summary estimate of AUC of 0.78 [78]. To be noticed that among the dif-
ferent studies, five different definitions of airway eosinophilia had been used, but 
either eosinophils ≥2% or 3% was used and this did not affect the accuracy of the 
test. Moreover, a subanalysis of the study showed the forest plots for blood eosino-
philia in detecting sputum eosinophilia in subgroup populations of asthmatics. 
Smoking habit, steroid-treated or untreated and asthma severity revealed a consid-
erable variability of positive thresholds of the marker. In severe asthma, only groups 
with the cut-point between 275 and 315 μL gave the highest sensibility and specific-
ity [79]. As the most robust clinical value of sputum eosinophilia is tailoring inhaled 
corticosteroids and reducing the frequency of asthma exacerbations, it is expected 
that blood eosinophilia to replace induced sputum in this context should yield a 
sensitivity and specificity of at least 90%, so that only a small portion of patients 
will be misclassified. One of the most evident limits in the role of blood eosinophilia 
as a biomarker comes for the cross-sectional nature of the study populations. 
Significant variability of blood eosinophil count in the same patient over time and 
according to treatment status must be taken into account.
5.3 Treatment of severe eosinophilic asthma
Asthma guidelines are recommending the use of sputum eosinophil count in 
severe asthma. The international ERS/ATS guidelines on the definition, evalu-
ation and treatment of severe asthma addressed the phenotypic management 
of severe asthma and evaluated the utility use of sputum eosinophilia to guide 
treatment. The document suggested that treatment guided by clinical criteria and 
sputum eosinophil counts should be performed in centers with experience in this 
procedure and in selected patients, allowing avoidance of inappropriate escala-
tion of treatment and waste of resources [62]. In the global strategy for asthma 
management and prevention (GINA) 2019 update, this concept is reinforced by 
claiming that treatment guided by sputum eosinophil count has the best benefits 
in patients with moderate-to-severe asthma requiring secondary care [1]. Within 
step 5 of treatment scale, adults with persistent symptoms or exacerbations despite 
high-dose ICS or ICS/LABA are advised to adjust treatment based on sputum 
eosinophilia >3%.
When a refractory or underline type 2 inflammation is proven in severe asthma, 
add-on biologic type 2 target treatment must be considered for patients with 
exacerbations or poor symptom control [1, 59]. Actually, sputum eosinophil count 
also provides an effective method to identify patients who will benefit from targeted 
therapy with anti–IL-5 monoclonal antibodies (mAbs). In patients with refractory 
eosinophilic asthma that had a sputum eosinophilia >3% DCC, despite high dose of 
inhaled corticosteroids, and at least 2 exacerbations in the last 2 years, with the need 
to make a short course of systemic corticosteroids, mepolizumab therapy reduces 
exacerbations and improves AQLQ scores [80]. Other studies confirmed the efficacy 
of anti-IL-5 mAb therapy in patients with asthma who had consistently increased 
eosinophil counts in sputum of greater than 2.5–3% on at least two occasions [81] .
Yet, the measurement of eosinophils in sputum or airway fluids may not truly 
reflect the contributions of airway tissue eosinophils. Actually, a study was assessed 
to understand whether induced sputum has the ability to distinguish the eosino-
philic and noneosinophilic phenotypes compared to bronchial biopsies in moderate 
and severe asthma. This study showed that among patients with severe asthma 
could identify a BrEos+ group with high mucosal eosinophils and a BrEos– group. 
Even if there was no a correlation between sputum eosinophil count and eosino-
phils found in the bronchial mucosa, there was a significant correlation between 
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the number of asthma exacerbations reported by the subjects with severe asthma 
during the year preceding the study and the percentage of sputum eosinophils [82]. 
This result is reflected by the fact that on one hand mepolizumab depleted <50% 
of bronchial tissue and bone marrow eosinophils in spite of its effect in reducing 
blood, BAL fluid and sputum eosinophils abolishing established airway eosinophil 
infiltration [83]. Among the explanation to this phenomenon, it can be supposed 
that eosinophils in the airway lumen may be in a different state of activation than in 
the bronchial mucosa or may reflect greater concentrations of intraluminal chemo-
kines such as eotaxin and RANTES or epithelial activation.
Another possible consequence of the supposed partial effect of mepolizumab 
over all the aspects of eosinophilic inflammation is that FEV1, symptoms and FENO 
levels were not affected [80]. On one hand, this means that these therapeutic strate-
gies may not be sufficient to reverse remodeling changes of severe asthma even if 
mepolizumab has been shown to decrease the deposition of tenascin, lumican and 
collagen III in the basal membrane of mild atopic asthmatics as well as the degree 
of TGF-β in the bronchoalveolar lavage fluid [43]. Accordingly, lung function was 
not expected to be positively modified by anti-IL-5 treatments in severe asthma and 
a meta-analysis of nine randomized, placebo-controlled, clinical trials including 
mepolizumab or reslizumab reported a mild absolute difference of FEV1 in favor of 
the anti-IL-5 treatment compared to placebo [84].
On the other hand, the persistently high level of FENO can guess, in a propor-
tion of eosinophilic refractory severe asthmatics, that the IL-5 pathway is not 
in these patients the predominant. This fact can explain why targeting the type 
2 phenotype on the IL4/IL13 pathway with dupilumab, a humanized MoAb to 
IL4-Ra, gave partially different results. When type 2 severe asthmatics with sputum 
eosinophilia >3% had been enrolled to be treated with dupilumab, the endpoints 
consisting of improvement of control (ACQ ), symptoms and FEV1 were reached. 
These clinical and functional results were coupled with decreasing FENO, eotaxin 3 
and IgE levels [85].
Another question is whether blood eosinophils are a good predictor of response 
to mepolizumab in patients with severe eosinophilic asthma. The DREAM study 
identified a blood eosinophil count of 300/mL or greater as a high predictive 
biomarker of response to mepolizumab [86].
In systemic corticosteroid severe asthma with persistent blood eosinophilia, at 
least 150 cells, the goal of reducing >75% of oral corticosteroid dose was reached in 
more than 40% of patients, confirming the role of persistent blood eosinophilia as 
predictor marker [87].
Benralizumab binds with high affinity to the alpha-chain of human IL-5R, 
blocking its activation and transduction and determining a neutralizing activ-
ity. Moreover, it is able to induce antibody-dependent cell-mediated cytotoxicity 
(ADCC) on NK cells that release cytotoxic mediators and cause eosinophil apop-
tosis [88]. A significant clinical efficacy in terms of reduction of annual exacerba-
tions, improvement of FEV1 and steroid-sparing effect was demonstrated in the 
clinical trials [89]. A threshold of >300 cells per mcl represents a useful marker 
for quantifying the advantage of this treatment in patients with steroid-dependent 
asthma. It has been supposed that benralizumab results in a complete depletion of 
eosinophils in the airway lumen and this can in part explain why in the registrative 
studies pre-bronchodilator FEV1 improved in the treatment groups. Actually, ben-
ralizumab is highly selective on eosinophil and basophil protein and gene-related 
immune signaling pathways [90] and not only reaches almost complete eosinophil 
eliminations at plasma levels but also determines the reduction of blood eosinophil 
precursors [91].
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6. Conclusions
The definition of eosinophilic asthma engages different models according to 
different contests [92]. However, a single common thread can be glimpsed in the 
ability of eosinophils to catch biological and clinical features that are crucial in each 
contest. Mouse and human allergic asthma models teach us that as the eosinophilic 
cascade can be dominant after acute exposition to triggers but only within the 
chronic stimulation, it contributes to deeper structural changes of the airways  
[11, 17]. The role of eosinophils in different phases of allergic asthma as well as the 
involving of Th2 cells, cytokines including IL5, IL4 and IL13 and chemokines has 
been smartly showed in the majority of the experimental studies. In addition, the 
mechanisms leading to AHR or persistent inflammation imply the need of sharing 
of different pathways of the Th2 cascade and the cross-talk between eosinophils 
and other immune cells [41]. The contribution of either IL-5–independent ways 
or the regulation of local or systemic eosinophilopoiesis has been addressed [40]. 
In real life, these phenomena can explain the ability of eosinophilic inflammation 
to be controlled by corticosteroid treatments, and, under certain circumstances, it 
becomes insensitive to this treatment.
Accordingly, in the context of severe asthma, eosinophilic airway inflamma-
tion becomes exceptionally deregulated and needs a biological approach to be 
controlled. The eosinophilic phenotype of asthma is currently defined by sputum 
examination that reveals eosinophilic airway inflammation. Generally, eosinophilic 
subtype of asthma may be defined as symptomatic asthma in the presence of airway 
eosinophilia and that is characterized by a good response to glucocorticosteroids. 
The efficacy of reducing exacerbations when corticosteroid treatment was guided 
according to the sputum eosinophils has addressed the point of eosinophilic target 
therapy in a subgroup of patients who encounter worse asthma control, higher use 
of healthcare resources, higher risk of exacerbations and the need of high-dose 
ICS or systemic corticosteroid treatment to be controlled. Continuous or bust oral 
corticosteroid exposure is associated to significant adverse effects that significantly 
impact on the patients’ outcome [66], highlighting the urgent need of sparing corti-
costeroid approaches. Even if limits in accuracy have been evidenced, blood eosino-
phils can be used in the clinic for detecting airway eosinophilia in uncontrolled 
severe asthma [78] and as eligibility criteria for anti–IL-5 target therapy. Therefore, 
new add-on therapies for severe asthma have showed to reduce both asthma exac-
erbation rate compared to standard of care and daily OCS use. Five biologicals have 
been now approved for severe eosinophilic asthma and can be applied depending 
on asthma phenotype and endotype [93]. As a consequence, the precision medicine 
and personalized therapy have become the best clue for treatment and monitoring 
the response by identification of suitable biomarkers in patients with more severe 
and refractory forms of asthma [94].
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